Biobetters and the Future Biologics Market - Despite their difficult approval pathway, biobetters offer the potential for innovation and decreased healthcare costs. - BioPharm International


Biobetters and the Future Biologics Market
Despite their difficult approval pathway, biobetters offer the potential for innovation and decreased healthcare costs.

BioPharm International
Volume 24, Issue 11, pp. 31-35


The development costs of a biosimilar product that meets the requirements of a strongly regulated market have been estimated by those developing such products to be $75–250 million and by the Federal Trade Commission to be $100–200 million (7,8). When considering the global registration of a biosimilar, one variable still to be assessed in these estimates is whether clinical trials will be required in each regulatory market. At present, the EMA has requested testing against a locally approved, European-labeled reference product and there are signs that FDA will require testing against a US-approved and labeled reference product. Duplication of the pivotal clinical trials is thus a possibility. In the US, the extent of data required to prove that a product is "interchangeable" is undefined, but it can be expected to be significantly greater than the requirements for a claim of "highly similar" to the reference product. With this high entry cost, a biosimilar will only be a viable prospect when the potential sales of that product exceed $250 million per year (9).

Table II: Market share value for biosimilars in Europe (10). HGF is human growth hormone, EPO is epoetin, and G-CSF is granulocyte colony stimulating factor.
Data from European experience with biosimilars can be examined to investigate the probable returns on the level of investment needed to bring a biosimilar to market. In Europe, a biosimilar is approved through the central process common to all member states, then each country decides whether the product may be substituted for the reference product and at what level that substitution may occur. Table II provides data for biosimilar market penetration in Europe, by country, in the second quarter of 2009. At this time, biosimilar human growth hormones (HGH) had been approved for three years, biosimilar epoetins (EPO) for two years, and biosimilar filgrastims (G-CSF) for less than nine months.

The relatively high penetration of G-CSF in a short period of time suggests that increased familiarity with biosimilars in the European market is improving uptake, but it could also reflect differing substitution concerns. What is noticeable is that the originator product maintains a significant market share in the face of biosimilar competition. There is no evidence of the dramatic erosion of sales seen in the patent cliffs of small-molecule originators.

Figure 2: Epoetin (EPO) sales in Germany following approval of the first biosimilars (data, ref. 11).
The second part of the picture for biosimilar sales is the number of entrants to the market and the period over which they launch products. With no equivalent of the Waxman–Hatch 180-day exclusivity period for the first generic competitor, the European experience has been that several biosimilar products enter the market at the same time. While this has in part been influenced by the timing of the development of the European biosimilar guidelines, the situation is likely to be mimicked in the US as guidelines are issued or market exclusivity or patent periods expire. Figure 2 shows the situation in Germany following the approval of the EPO biosimilars Binocrit and Mircera on Sept. 28, 2007, and Silapo and Retacrit on Dec. 18, 2007. Although overall sales value for biosimilar EPO products has increased since 2008, the split between the manufacturers has been maintained.

Based on a European market of approximately $600 million for EPO, extrapolation of these figures would likely give a biosimilar uptake of $185 million, with the single biggest seller obtaining European sales of $100 million. These figures are theoretical; for an example of real sales figures, Sandoz, which has been the leader in the biosimlar business since launching Omnitrope (HGH) in Europe in 2006 and in the US in 2007, achieved combined global sales of the biosimilars Omnitrope, Binocrit (EPO), and Zarzio (G-CSF) of $185 million in 2010 (12).

The key factor in these calculations is the uptake per country, which is governed by the substitution policy. Including the potential US market, which is approximately 1.5 times that of Europe, achieving a sales target of $250 million per year for a biosimilar will only be possible if a product is granted interchangeable status with the originator in the US market. The requirements for interchangeable status have yet to be set but they can be expected to be very challenging.

blog comments powered by Disqus



Bristol-Myers Squibb and Five Prime Therapeutics Collaborate on Development of Immunomodulator
November 26, 2014
Merck Enters into Licensing Agreement with NewLink for Investigational Ebola Vaccine
November 25, 2014
FDA Extends Review of Novartis' Investigational Compound for Multiple Myeloma
November 25, 2014
AstraZeneca Expands Biologics Manufacturing in Maryland
November 25, 2014
GSK Leads Big Pharma in Making Its Medicines Accessible
November 24, 2014
Author Guidelines
Source: BioPharm International,
Click here